Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
Gene Therapy - PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine a and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
Genentech, Inc. - Phase III Study Showed Patients Lived Longer Without Advanced Lung Cancer Progressing When Tarceva Was Added to Avastin as First-Line Maintenance Therapy
Lantheus Medical Imaging, Inc. - Lantheus Medical Imaging, Inc. Completes Enrollment of CaRES Registry to Further Evaluate DEFINITY® in Patients with Suboptimal Echocardiograms
Lung Cancer - Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
Lung Cancer - New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography
Merck KGaA - Merck KGaA: Follow-Up From Stimuvax Study Provides Long-Term Safety Data In Advanced Lung Cancer Patients Receiving Treatment for Up To 8.2 Years
Non-Small Cell Lung Cancer - ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer
OSI Pharmaceuticals, Inc. - Data from the Phase III ATLAS Study Show Tarceva in Combination with Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer
Pfizer Inc - Pfizer Data Identify Certain Lung Cancer Patients Who May Benefit from Treatment with Figitumumab
Pfizer Inc - Pfizer Presents Data With Novel Investigational Agents In Select Patient Groups With Non-Small Cell Lung Cancer
Sarcoma - Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
Tuberculosis - Data On Investigational Drug TMC207 for Treatment of MDR-Tuberculosis, Published in New England Journal of Medicine